Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
No abstract available

Keywords: arthritis, rheumatoid; autoimmune diseases; autoimmunity; lupus erythematosus, systemic; spondylitis, ankylosing.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / mortality*
  • Coronavirus Infections / physiopathology
  • Female
  • Glucocorticoids / therapeutic use
  • Hospitalization / statistics & numerical data
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Intensive Care Units
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / mortality*
  • Pneumonia, Viral / physiopathology
  • Rheumatic Diseases / complications
  • Rheumatic Diseases / drug therapy*
  • Rituximab / therapeutic use
  • SARS-CoV-2
  • Spain
  • Spondylarthropathies / complications
  • Spondylarthropathies / drug therapy
  • Tumor Necrosis Factor Inhibitors / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Glucocorticoids
  • Interleukin 1 Receptor Antagonist Protein
  • Janus Kinase Inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Rituximab
  • Hydroxychloroquine
  • secukinumab
  • Methotrexate